» Articles » PMID: 38504961

Complete Blood Cell Count-Derived Inflammation Biomarkers in Patients with Xanthelasma Palpebrarum

Overview
Journal Beyoglu Eye J
Publisher Kare Publishing
Specialty Ophthalmology
Date 2024 Mar 20
PMID 38504961
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Xanthelasma palpebrarum (XP) is the most common type of cutaneous xanthoma, characterized by yellowish cutaneous plaques commonly located near the medial canthus of the eyelid. Although dyslipidemia significantly contributes to its development, inflammation is also believed to be another element in the pathogenesis, especially in normolipidemic patients. Recently, cell counts derived from complete blood counts have been identified as indicators of systemic inflammatory conditions and have also been under discussion concerning their relevance to ocular diseases. This study aimed to assess inflammation indices derived from complete blood cell counts (CBC) in XP patients with normal lipid levels.

Methods: Patients who had been referred to the oculoplasty department with the diagnosis of XP between January 2020 and January 2023 and age-matched control subjects were retrospectively reviewed. Patients who had abnormal lipid profiles and systemic diseases such as diabetes mellitus, hypertension, malignancy, cardiovascular diseases, systemic infections, and inflammatory diseases were not included in the study. CBC parameters were analyzed and compared between the groups.

Results: The study comprised 27 normolipidemic patients with XP and 27 age-matched healthy individuals as the control group. There were no statistically significant differences between the two groups in terms of age (p=0.143). The mean hemoglobin, neutrophil, monocyte, lymphocyte, platelet, neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, systemic immune-inflammation index, and aggregate index of systemic inflammation values were higher in the patient group, but the differences were not statistically significant (p>0.05). The mean red cell distribution width and platelet-to-lymphocyte ratio appeared to be lower in the patient group compared to the control group; however, no significant differences were observed between the two groups (p=0.272, p=0.387, respectively).

Conclusion: This study might offer insights into the pathogenesis of XP, yet numerous questions remain unanswered, awaiting further investigation in future studies.

References
1.
Govorkova M, Milman T, Ying G, Pan W, Silkiss R . Inflammatory Mediators in Xanthelasma Palpebrarum: Histopathologic and Immunohistochemical Study. Ophthalmic Plast Reconstr Surg. 2017; 34(3):225-230. PMC: 6704479. DOI: 10.1097/IOP.0000000000000921. View

2.
Rohrich R, Janis J, Pownell P . Xanthelasma palpebrarum: a review and current management principles. Plast Reconstr Surg. 2002; 110(5):1310-4. DOI: 10.1097/01.PRS.0000025626.70065.2B. View

3.
Zak A, Zeman M, Slaby A, Vecka M . Xanthomas: clinical and pathophysiological relations. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014; 158(2):181-8. DOI: 10.5507/bp.2014.016. View

4.
Raulin C, Schoenermark M, Werner S, Greve B . Xanthelasma palpebrarum: treatment with the ultrapulsed CO2 laser. Lasers Surg Med. 1999; 24(2):122-7. DOI: 10.1002/(sici)1096-9101(1999)24:2<122::aid-lsm7>3.0.co;2-6. View

5.
Laftah Z, Al-Niaimi F . Xanthelasma: An Update on Treatment Modalities. J Cutan Aesthet Surg. 2018; 11(1):1-6. PMC: 5921443. DOI: 10.4103/JCAS.JCAS_56_17. View